194 related articles for article (PubMed ID: 37970806)
21. Rapid pH-responsive self-disintegrating nanoassemblies balance tumor accumulation and penetration for enhanced anti-breast cancer therapy.
Li J; Wang Y; Xu C; Yu Q; Wang X; Xie H; Tian L; Qiu Y; Guo R; Lu Z; Li M; He Q
Acta Biomater; 2021 Oct; 134():546-558. PubMed ID: 33882357
[TBL] [Abstract][Full Text] [Related]
22. Increased Toxicity of Doxorubicin Encapsulated into pH-Responsive Poly(β-Amino Ester)-Functionalized MCM-41 Silica Nanoparticles.
Ávila-Ortega A; Carrillo-Cocom LM; Olán-Noverola CE; Nic-Can GI; Vilchis-Nestor AR; Talavera-Pech WA
Curr Drug Deliv; 2020; 17(9):799-805. PubMed ID: 32723272
[TBL] [Abstract][Full Text] [Related]
23. Tailor-made legumain/pH dual-responsive doxorubicin prodrug-embedded nanoparticles for efficient anticancer drug delivery and in situ monitoring of drug release.
Li Y; Niu Y; Zhu J; Gao C; Xu Q; He Z; Chen D; Xu M; Liu Y
Nanoscale; 2020 Jan; 12(4):2673-2685. PubMed ID: 31942900
[TBL] [Abstract][Full Text] [Related]
24. Facile strategy by hyaluronic acid functional carbon dot-doxorubicin nanoparticles for CD44 targeted drug delivery and enhanced breast cancer therapy.
Li J; Li M; Tian L; Qiu Y; Yu Q; Wang X; Guo R; He Q
Int J Pharm; 2020 Mar; 578():119122. PubMed ID: 32035259
[TBL] [Abstract][Full Text] [Related]
25. Preparation of Modified Chitosan-based Nanoparticles for Efficient Delivery of Doxorubicin and/or Cisplatin to Breast Cancer Cells.
Matalqah SM; Aiedeh K; Mhaidat NM; Alzoubi KH; Al-Husein BA
Curr Cancer Drug Targets; 2022; 22(2):133-141. PubMed ID: 35081892
[TBL] [Abstract][Full Text] [Related]
26. Synthesis of a targeted, dual pH and redox-responsive nanoscale coordination polymer theranostic against metastatic breast cancer
Falsafi M; Hassanzadeh Goji N; Sh Saljooghi A; Abnous K; Taghdisi SM; Nekooei S; Ramezani M; Alibolandi M
Expert Opin Drug Deliv; 2022 Jun; 19(6):743-754. PubMed ID: 35616345
[TBL] [Abstract][Full Text] [Related]
27. Ultrasmall gold nanosatellite-bearing transformable hybrid nanoparticles for deep tumor penetration.
Son S; Deepagan VG; Shin S; Ko H; Min J; Um W; Jeon J; Kwon S; Lee ES; Suh M; Lee DS; Park JH
Acta Biomater; 2018 Oct; 79():294-305. PubMed ID: 30134209
[TBL] [Abstract][Full Text] [Related]
28. pH-responsive Sulfated Hyaluronic Acid Nanoparticles Targeting Tumor Cells and CAFs for the Treatment of Breast Cancer.
Wang D; Wu J; Qi C; Dong J; Ding X; Yu G; Liu S; Zhang B; Gao Z; Wei X; Liu H
Recent Pat Anticancer Drug Discov; 2022; 18(2):200-210. PubMed ID: 35538821
[TBL] [Abstract][Full Text] [Related]
29. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
[TBL] [Abstract][Full Text] [Related]
30. Low density lipoprotein-inspired nanostructured lipid nanoparticles containing pro-doxorubicin to enhance tumor-targeted therapeutic efficiency.
Li W; Fu J; Ding Y; Liu D; Jia N; Chen D; Hu H
Acta Biomater; 2019 Sep; 96():456-467. PubMed ID: 31260821
[TBL] [Abstract][Full Text] [Related]
31. Layer-by-layer pH-sensitive nanoparticles for drug delivery and controlled release with improved therapeutic efficacy
Men W; Zhu P; Dong S; Liu W; Zhou K; Bai Y; Liu X; Gong S; Zhang S
Drug Deliv; 2020 Dec; 27(1):180-190. PubMed ID: 31924103
[TBL] [Abstract][Full Text] [Related]
32. Stepwise targeted drug delivery to liver cancer cells for enhanced therapeutic efficacy by galactose-grafted, ultra-pH-sensitive micelles.
Yan G; Wang J; Hu L; Wang X; Yang G; Fu S; Cheng X; Zhang P; Tang R
Acta Biomater; 2017 Mar; 51():363-373. PubMed ID: 28087485
[TBL] [Abstract][Full Text] [Related]
33. Tailored design of multifunctional and programmable pH-responsive self-assembling polypeptides as drug delivery nanocarrier for cancer therapy.
Wang TW; Yeh CW; Kuan CH; Wang LW; Chen LH; Wu HC; Sun JS
Acta Biomater; 2017 Aug; 58():54-66. PubMed ID: 28606810
[TBL] [Abstract][Full Text] [Related]
34. Conjugated Polymer Nanoparticles Based on Copper Coordination for Real-Time Monitoring of pH-Responsive Drug Delivery.
Li J; Du N; Tan Y; Hsu HY; Tan C; Jiang Y
ACS Appl Bio Mater; 2021 Mar; 4(3):2583-2590. PubMed ID: 35014375
[TBL] [Abstract][Full Text] [Related]
35. Dual-responsive mPEG-PLGA-PGlu hybrid-core nanoparticles with a high drug loading to reverse the multidrug resistance of breast cancer: an in vitro and in vivo evaluation.
Xu H; Yang D; Cai C; Gou J; Zhang Y; Wang L; Zhong H; Tang X
Acta Biomater; 2015 Apr; 16():156-68. PubMed ID: 25662165
[TBL] [Abstract][Full Text] [Related]
36. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
[TBL] [Abstract][Full Text] [Related]
37. Decapeptide functionalized targeted mesoporous silica nanoparticles with doxorubicin exhibit enhanced apoptotic effect in breast and prostate cancer cells.
Tambe P; Kumar P; Paknikar KM; Gajbhiye V
Int J Nanomedicine; 2018; 13():7669-7680. PubMed ID: 30538451
[TBL] [Abstract][Full Text] [Related]
38. Redox and pH dual sensitive bone targeting nanoparticles to treat breast cancer bone metastases and inhibit bone resorption.
Zhao YP; Ye WL; Liu DZ; Cui H; Cheng Y; Liu M; Zhang BL; Mei QB; Zhou SY
Nanoscale; 2017 May; 9(19):6264-6277. PubMed ID: 28470315
[TBL] [Abstract][Full Text] [Related]
39. Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood-Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor-Associated Macrophages.
Zhang T; Lip H; He C; Cai P; Wang Z; Henderson JT; Rauth AM; Wu XY
Adv Healthc Mater; 2019 Sep; 8(18):e1900543. PubMed ID: 31348614
[TBL] [Abstract][Full Text] [Related]
40. Targeted delivery by pH-responsive mPEG-S-PBLG micelles significantly enhances the anti-tumor efficacy of doxorubicin with reduced cardiotoxicity.
Feng Q; Xu J; Liu X; Wang H; Xiong J; Xiao K
Drug Deliv; 2021 Dec; 28(1):2495-2509. PubMed ID: 34842005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
